The Interaction of lncRNA-HEIH and lncRNA-HULC with HBXIP in Hepatitis B Patients.

Lingjuan Ruan,Lilai Zhao,Qiuping Bai,Lifei Huang,Zongjun Lv,Xiaocheng Pan,Qiang Wang,Anmin Zhang

doi:10.1155/2018/9187316

Abstract

Hepatitis B virus (HBV) infection is a major risk factor for the development of hepatic cirrhosis (HC) and hepatocellular carcinoma (HCC), which are associated with very high morbidity and mortality rates worldwide. Many studies have shown that long noncoding RNAs (lncRNAs) that are highly expressed in HCC (lncRNA-HEIH) and highly upregulated in liver cancer (lncRNA-HULC) have been implicated in the development and progression of hepatitis B-related HC and HCC. In this study, reverse transcription and quantitative PCR were used to detect the expression of lncRNA-HEIH and lncRNA-HULC and western blot analysis to detect the expression of hepatitis B X-interacting protein (HBXIP). RNA immunoprecipitation was used to detect the interaction of HBXIP with lncRNA-HULC and lncRNA-HEIH. The results showed that lncRNA-HEIH, lncRNA-HULC, and HBXIP were upregulated in hepatitis B patients, particularly those with hepatitis B-related HCC. Both lncRNA-HEIH and lncRNA-HULC interacted with HBXIP. These results suggest that lncRNA-HEIH and lncRNA-HULC interact with HBXIP in hepatitis B-related diseases.

Highlights

Hepatitis B virus (HBV) infection remains a major public health concern, affecting more than 350 million people worldwide, despite the advent of effective vaccines and other control measures [1,2,3]
Chronic HBV infection is characterized by the detection of serum hepatitis B surface antigen (HBsAg) after 6 months of infection with continuous liver inflammation and activation of fibrogenic processes, which can lead to hepatic cirrhosis (HC), decompensated liver disease, and the development of hepatocellular carcinoma (HCC) in 25%–40% of HBV carriers [3]
According to the RTqPCR results, the expression levels of LncRNA-HEIH and LncRNA-HULC were significantly upregulated in the peripheral blood of HBV-positive patients (HBV, HBV + HC, and HBV + HCC groups), as compared to the control group (p < 0 05, Figure 1(a))

Summary

Introduction

Hepatitis B virus (HBV) infection remains a major public health concern, affecting more than 350 million people worldwide, despite the advent of effective vaccines and other control measures [1,2,3]. It is urgent to identify new and promising diagnostic markers and therapeutic targets for HBV-related diseases. HBV is a double-stranded DNA virus containing four partially overlapping open reading frames, encoding the C, S, and X proteins, and a viral DNA polymerase [4]. Among these four proteins, only the X protein (HBX) has been clearly associated with tumorigenesis [5]. The hepatitis B X-interacting protein (HBXIP) was originally identified by its interaction with the C-terminus of the HBX, which has been found to enhance the growth of hepatoma cells and promote tumorigenesis [6]

Objectives

Methods

Results

Conclusion